Evaluating the therapeutic potential of mTOR inhibitors using mouse genetics.

[1]  L. Chin,et al.  Non-germline genetically engineered mouse models for translational cancer research , 2010, Nature Reviews Cancer.

[2]  D. Guertin,et al.  Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy , 2010, Oncogene.

[3]  K. Shokat,et al.  New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs). , 2010, Current topics in microbiology and immunology.

[4]  R. Abraham,et al.  Targeting mTOR globally in cancer: Thinking beyond rapamycin , 2009, Cell cycle.

[5]  Jeffrey A. Engelman,et al.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.

[6]  Crafford A. Harris,et al.  A kinase-dead knock-in mutation in mTOR leads to early embryonic lethality and is dispensable for the immune system in heterozygous mice , 2009, BMC Immunology.

[7]  D. Guertin,et al.  mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. , 2009, Cancer cell.

[8]  M. Loda,et al.  Differential Requirement of mTOR in Postmitotic Tissues and Tumorigenesis , 2009, Science Signaling.

[9]  Chun-Peng Liao,et al.  Pten null prostate tumorigenesis and AKT activation are blocked by targeted knockout of ER chaperone GRP78/BiP in prostate epithelium , 2008, Proceedings of the National Academy of Sciences.

[10]  E. Casanova,et al.  Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. , 2008, Cell metabolism.

[11]  David M Sabatini,et al.  Defining the role of mTOR in cancer. , 2007, Cancer cell.

[12]  D. Guertin,et al.  Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. , 2006, Developmental cell.

[13]  K. Inoki,et al.  Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. , 2006, Genes & development.

[14]  J. Woo,et al.  Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. , 2006, Developmental cell.

[15]  Daniel J. Freeman,et al.  Genetic background controls tumor development in PTEN-deficient mice. , 2006, Cancer research.

[16]  K. Okkenhaug,et al.  Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation , 2006, Nature.

[17]  D. Sabatini,et al.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. , 2006, Molecular cell.

[18]  Ximing J. Yang,et al.  The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. , 2006, Genes & development.

[19]  R. Parsons,et al.  Hypomorphic Mutation of PDK1 Suppresses Tumorigenesis in PTEN+/− Mice , 2005, Current Biology.

[20]  G. Thomas,et al.  Disruption of the Mouse mTOR Gene Leads to Early Postimplantation Lethality and Prohibits Embryonic Stem Cell Development , 2004, Molecular and Cellular Biology.

[21]  M. Murakami,et al.  mTOR Is Essential for Growth and Proliferation in Early Mouse Embryos and Embryonic Stem Cells , 2004, Molecular and Cellular Biology.

[22]  M. Rubin,et al.  Prostate Pathology of Genetically Engineered Mice: Definitions and Classification. The Consensus Report from the Bar Harbor Meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee , 2004, Cancer Research.

[23]  P. Nelson,et al.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. , 2003, Cancer cell.

[24]  P. Roy-Burman,et al.  Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation , 2001, Mechanisms of Development.

[25]  Kathryn E. Hentges,et al.  The flat-top gene is required for the expansion and regionalization of the telencephalic primordium. , 1999, Development.

[26]  C. Cordon-Cardo,et al.  Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[27]  T. Mak,et al.  High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice , 1998, Current Biology.

[28]  Carlos Cordon-Cardo,et al.  Pten is essential for embryonic development and tumour suppression , 1998, Nature Genetics.